Literature DB >> 23441991

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

Roberto Gallego-Pinazo1, Rosa Dolz-Marco, Sebastián Martínez-Castillo, J Fernando Arévalo, Manuel Díaz-Llopis.   

Abstract

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrolimus in a third step; biological anti-TNF drugs in fourth position; and a last one with cyclophosphamide and chlorambucil. In the present review we go through the main characteristics and complications of all these treatments and make a rational of this five-step treatment protocol for non-infectious posterior uveitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23441991     DOI: 10.2174/1871528111312010006

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  16 in total

1.  Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.

Authors:  Eliya Levinger; Omer Trivizki; Yonathan Shachar; Samuel Levinger; David Verssano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-04       Impact factor: 3.117

Review 2.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

Review 3.  Pediatric uveitis: new and future treatments.

Authors:  Preema J Mehta; Janet L Alexander; H Nida Sen
Journal:  Curr Opin Ophthalmol       Date:  2013-09       Impact factor: 3.761

Review 4.  Immunopharmacotherapy of non-infectious uveitis: where do we stand?

Authors:  Rupesh Agrawal; Cecilia Lee; Sumita Phatak; Carlos Pavesio
Journal:  Expert Opin Biol Ther       Date:  2014-09-22       Impact factor: 4.388

5.  Achieving Quiescence with Fluocinolone Implants.

Authors:  Freia McGregor; Andrew D Dick; Tomas Burke
Journal:  Case Rep Ophthalmol       Date:  2021-05-10

Review 6.  Ocular involvement in primary immunodeficiency diseases.

Authors:  Sima Hosseinverdi; Hassan Hashemi; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2013-11-30       Impact factor: 8.542

Review 7.  Noninfectious uveitis: strategies to optimize treatment compliance and adherence.

Authors:  Rosa Dolz-Marco; Roberto Gallego-Pinazo; Manuel Díaz-Llopis; Emmett T Cunningham; J Fernando Arévalo
Journal:  Clin Ophthalmol       Date:  2015-08-18

8.  Pentacam corneal densitometry-guided treatment of adenoviral corneal subepithelial infiltrates: a comparative study between transepithelial phototherapeutic keratectomy and topical tacrolimus.

Authors:  Tarek Roshdy Elhamaky
Journal:  Int Ophthalmol       Date:  2020-08-27       Impact factor: 2.031

Review 9.  Management of pediatric uveitis.

Authors:  Bailey A Wentworth; Clovis A Freitas-Neto; C Stephen Foster
Journal:  F1000Prime Rep       Date:  2014-06-02

Review 10.  Pharmacotherapy for uveitis: current management and emerging therapy.

Authors:  Robert J Barry; Quan Dong Nguyen; Richard W Lee; Philip I Murray; Alastair K Denniston
Journal:  Clin Ophthalmol       Date:  2014-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.